Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120417 · ClinicalTrials.gov registry record · Phase 2
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT02120417 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 149 participants.
The verdict
NCT02120417, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment with capecitabine alone.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120417
The ClinicalTrials.gov registry entry for NCT02120417 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02120417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120417 about?
NCT02120417 is a clinical study titled "A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer". This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment with capecitabin...
What is the current status of trial NCT02120417?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2014-05. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02120417?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02120417?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.